Physician profile
Mustafa Nakawa
NPI 1558717603
$1,152.40
in general payments reported to CMS, 2019-2025
13 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Obesity Medicine (Family Medicine) provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.63 · 2020: $14.22 · 2021: $64.73 · 2022: $226 · 2023: $367 · 2024: $330 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.71 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $371.53 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Currax Pharmaceuticals LLC | $317.28 | 2022-2025 | Contrave, Nexletol |
| Abiomed | $85.86 | 2024-2025 | Impella |
| Lilly USA, LLC | $77.35 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $75.38 | 2023-2024 | |
| Pfizer INC. | $55.99 | 2020-2025 | |
| Abbott Laboratories | $47.65 | 2022 | |
| Inspire Medical Systems, INC. | $41.83 | 2023 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $21.41 | 2024 | Airsupra |
| Glaxosmithkline, LLC. | $17.91 | 2024 | Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $14.58 | 2024 | Voquezna |
| Therapeuticsmd, INC. | $12.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mustafa Nakawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.